IRB/IEC

FDA inspection findings frequently highlight issues where delegation of authority was unclear or back-up investigators were not appropriately trained or documented. To prevent such compliance gaps, sponsors must establish a robust process for back-up investigator nomination, training, and documentation.

According to ClinicalTrials.gov, trials that include named and trained back-ups at each site report fewer disruptions in enrollment and protocol deviations.

Selection Criteria for Back-Up Investigators

Identifying suitable back-up investigators begins with understanding the unique requirements of the rare disease protocol. Ideal candidates should have:

• Medical credentials equivalent to the PI (typically MD or equivalent)
• Prior experience in rare disease research or complex protocols
• Availability during the trial duration, including flexible scheduling
• Communication skills for informed consent and patient interaction

In some instances, senior fellows or subspecialty clinicians within the same institution may be nominated and trained to serve as back-up investigators, provided they meet all regulatory qualifications.

Designing a Back-Up Investigator Training Program

Back-up investigators must undergo structured and documented training similar to the PI. A comprehensive training plan should cover:

• Protocol training: Including endpoints, visit windows, and eligibility criteria
• Informed consent process: Ensuring ethical and regulatory compliance
• Safety monitoring: Reporting SAEs, AEs, and adherence to DSMB guidelines
• Data entry systems: Including EDC, ePRO, or IVRS/IRT platforms
• IP accountability: Storage, dispensing, and return procedures

Training can be delivered via a combination of live investigator meetings, recorded modules, protocol-specific workshops, and site initiation visits (SIVs).

Documenting and Delegating Responsibilities

All trained back-up investigators must be included in the Site Delegation Log (SDL) and their CVs, GCP certificates, and training logs filed in the Trial Master File (TMF). Delegated tasks must be clearly defined and aligned with the site’s SOPs and protocol requirements.

Before performing any trial-related activity, the back-up investigator must:

• Be approved by the sponsor and IRB/IEC
• Be granted access to trial systems and supplies
• Have full access to previous patient records and site correspondence

In one rare metabolic disorder trial, the seamless transition to a back-up investigator after the sudden retirement of the PI allowed uninterrupted dosing of patients and maintained regulatory compliance with zero protocol deviations.

Using Simulation Drills and SOPs for Readiness

To ensure readiness, some sponsors conduct simulation drills where back-up investigators walk through patient visits or mock monitoring sessions. This helps assess:

• Familiarity with the protocol flow
• Comfort with medical documentation and source verification
• Ability to interact with site staff and external monitors

Such exercises not only validate readiness but also improve confidence and retention of training. These activities can be incorporated into the site’s SOPs as part of clinical trial continuity planning.

Ensuring Continuity During Investigator Transitions

When a transition occurs—whether planned or due to emergency—the handover must be managed meticulously:

• Update IRB/IEC and regulatory authorities with change of investigator (COI) forms
• Ensure clear documentation of the date of transition
• Conduct overlapping shadow visits where feasible
• Reassign all responsibilities in clinical systems (e.g., CTMS, EDC)

Delays in formalizing transitions often lead to data integrity concerns or audit findings, especially in sensitive trials where patient safety is closely monitored.

Conclusion: Building Resilient Trial Teams for Rare Disease Success

Back-up investigators play a pivotal role in ensuring continuity, compliance, and trial integrity in rare disease research. Their proactive training, integration into site operations, and documentation within trial records serve as a critical buffer against disruptions.

By investing in robust back-up strategies, sponsors and sites can not only comply with GCP requirements but also maintain trust with patients and regulators—an essential pillar in the development of therapies for the rare disease community.